UK NICE recommends Seagen’s tucatinib for advanced breast cancer

According to the final NICE draft guidance, tucatinib will benefit nearly 400 patients in the region. Credit: Nephron / Wikimedia.

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Seagen’s tucatinib for the treatment of individuals with advanced breast cancer.

Free Whitepaper

Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States

Cell and gene therapies (CGT) have seen expansive clinical development and revenue growth over the past 5 years across various therapeutic areas. With the approval of 12 new therapies and the initiation of over 2,900 clinical trials between the analysis period of 2016 -2021, it is evident there is extensive investment in the innovation of CGT. Notably, oncology is the leading therapeutic area, with the highest percentage of new clinical development year-on year compared to other CGT therapy areas, indicating a high level of unmet needs and increased industry investment in the space. Access GlobalData’s new whitepaper, Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States to gain a better understanding of the developments, challenges and opportunities in CGT including exclusive insights on promising future oncology CGT assets in development. The white paper covers:

The key takeaways of cell and gene therapy
Extensive background on the uptake of cell and gene therapy
Insights and outlook of cell and gene therapy trials in the US
An analysis of the top oncology cell and gene therapy assets and developers

Enter your details here to receive the free whitepaper.

By GD50 Custom

By downloading this case study, you acknowledge that GlobalData may share your information with GD50 Custom and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tucatinib will be offered as an option to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread in individuals who have been treated with two or more anti-HER2 therapies.

The recommended dosage is two 150mg tablets given twice a day along with anti-cancer therapies, trastuzumab and capecitabine.

Tucatinib combination acts by hindering a particular region of the HER2 gene in cancer cells, which prevents cell growth and spread.

According to the final draft guidance published by NICE, the new therapy will be available for routine usage in the National Health Service (NHS) and nearly 400 patients will benefit from it.

In the prior draft guidance, NICE did not advise the use of the tucatinib combination following which the company provided an additional assessment to show its benefit, particularly in brain metastases patients.

Furthermore, the company offered an additional discount on tucatinib’s price to be paid by the NHS.

Final guidance on tucatinib plus trastuzumab and capecitabine from NICE is anticipated next month.

NICE Centre for Health Technology Evaluation programme director Helen Knight said: “Tucatinib is a promising, innovative new treatment that has the potential to increase the length of time before the disease gets worse and how long people live overall.

“And because tucatinib is able to cross an intact blood-brain barrier it offers people whose cancer has spread to their brain real hope of extending their lives and improving their quality of life.”

In January, NICE granted approval to pembrolizumab (Keytruda) plus chemotherapy drugs, carboplatin and paclitaxel, for the treatment of a type of non-small cell lung cancer.